Research Progress of BRAF Fusion in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.101.28
- Author:
Ping XIAO
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Fusion;
Lung neoplasms;
V-Raf murine sarcoma viral oncogene homolog B1
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms/pathology*;
Mutation;
Proto-Oncogene Proteins B-raf/genetics*
- From:
Chinese Journal of Lung Cancer
2023;26(10):782-788
- CountryChina
- Language:Chinese
-
Abstract:
In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients.
.
